High Court Ruling Limits International Reach of Patent Laws
The Supreme Court on Wednesday sided with California-based Life Technologies Corp . in a patent infringement case that limits the international reach of U.S. patent laws.
Category Archives: Biotech
Innate Immunotherapeutics And Tom Price
What does the Department of Health and Human Services have in common with a small bio-tech company based in Australia? Well, they both appear to be controlled by key figures in the Trump transition team. Innate Immunotherapeutics is a small firm specializing in the development and design of a clinical stage biotechnology drug that targets the human innate immune system.
Senators demand better information from DEA on opioid campaign
Seven U.S. senators sharply criticized the Drug Enforcement Administration on Wednesday for failing to answer questions about enforcement actions against pharmaceutical companies accused of violating laws designed to prevent painkillers from reaching the black market. "We received an insufficient response that ignored those questions almost entirely and recited boilerplate information about the DEA's mission," said the letter to the acting DEA administrator, Chuck Rosenberg.
Supreme Court adds 16 cases to docket
The Court granted review on a variety of civil and criminal cases. The civil cases include both substantive and procedural questions.
Widespread Drug Price Increases Point to Collusion, Study Finds
About one in 19 generic drugs sold in the U.S. during the past three years have undergone major price hikes that may be consistent with collusion, according to a wide-ranging study that comes in the middle of a sprawling Justice Department investigation into pharmaceutical price-fixing. Fideres Partners LLP, a London-based consultancy that works with law firms to bring litigation against companies, analyzed price moves in 1,670 generic drugs sold in the U.S. from 2013 to 2016.
US Court of Appeals: States and counties can ban GMO crops despite federal laws
The entire organic community of the United States just won a massive victory that many may not yet even realize. Even though the DARK Act was passed by Obama and some Senate goons to prohibit labeling of GMOs nationwide, the US Court of Appeals just passed a law that enables states and counties to completely ban genetically engineered crops from ever being planted in the first place.
This Marijuana Company’s in Hot Water With the DOJ
Ongoing investigations into the marketing of its once high-flying fentanyl spray, Subsys, have taken a lot of the luster off Insys Therapeutics ' attempt to reshape marijuana's use as medicine. Today, investigations by the Justice Department led to the arrest of former Insys Therapeutics employees, including former CEO Michael Babich, casting more uncertainty on this company's future.
Trump Win Doesn’t Get Pharma Off the Hook on High Drug Prices
Even with a presumably business-friendly president-elect in Donald Trump, drugmakers that have been battered by criticism over high prices in the past year are bracing for Republican and Democratic lawmakers to take aim at the industry. Although Trump's brief health plan released last week on his transition's website doesn't mention drug prices, he has previously voiced support for having the government negotiate prices in Medicare, and allowing the re-importation of cheaper treatments from other countries -- two proposals the pharmaceutical industry has long opposed.
Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who…
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased American Depositary Shares of Teva between February 10, 2015 and November 3, 2016 . The case, Galmi v. Teva Pharmaceutical Industries Limited et al , No.
Bernie Is So Not Done
If you're feeling bereft, take note: Bernie Sanders is still here loudly fighting the good fight, this week blasting the avarice of Big Pharma so persuasively he sent their stock prices plunging to a seven-month low. After battling Big Pharma for decades - pillorying the makers of the emergency allergy injection EpiPen for obscenely jacking up their prices, recently calling out another company's price hikes on leukemia drugs, and campaigning this fall to stop price-gouging by seen by many as Ground Zero for drug companies and their 1,266 D.C. lobbyists - Bernie isn't letting up.
Sanders Takes Aim at Insulin Makers in Latest Price Attack
Makers of insulin became the latest target for Senator Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices. Shares of Eli Lilly & Co.
Eli Lilly (LLY) Stock Falls, Sanders Criticizes Drug Pricing
Shares of Eli Lilly were sliding in early-afternoon trading on Tuesday after Senator Bernie Sanders criticized the price increase of the company's Humalog insulin. Why has the price of Humalog insulin gone up 700% in 20 years? It's simple.
Realistically, Clinton Is Not Anti-Healthcare-Stocks
These bearish sentiments first started with Valeant Pharmaceuticals, then Gilead and Turing Pharmaceuticals, and are now adversely affecting ETFs that hold any of these or their peers/competitors. It is my contention that the market is accustomed to common arbitrage opportunities, and when an even-driven opportunity emerges masking itself as a headwind, investors flee.
Experts hope mosquito-borne bacteria can beat the Zika virus
In this Monday, Feb. 22, 2016 file photo, Bill and Melinda Gates talk to reporters about the 2016 annual letter from their foundation, the Bill and Melinda Gates Foundation, in New York. Researchers are trying to infect mosquitoes in Brazil and Colombia with a type of bacteria that could prevent them from spreading Zika virus and other dangerous diseases.
US stocks jump as energy companies and Apple move higher
U.S. stocks are climbing in Monday trading as energy companies rise in tandem with the price of oil. Materials companies are also moving up.
EpiPen investigation shows need for greater pricing transparency, other reforms
For months, my office has heard from families concerned about their ability to afford a device they desperately need in the event that a loved one suffers a sudden allergic reaction. Parents should not have to worry about whether they can afford an EpiPen for their children.
For Pfizer, Bigger as One May Be Better Than Smaller With Two
By deciding not to split in two after a lengthy evaluation, the New York-based drugmaker is keeping greater leverage with the health insurers and pharmacy benefit managers that have gained increasing power since it first considered a breakup years ago. Had it broken up, Pfizer would have turned into one company with older and generic products, and another with newer products.
Mylan CEO Faces Tough Questioning in EpiPen Hearing
Mylan NV CEO Heather Bresch faced tough questioning Wednesday from Republicans and Democrats in Congress probing price increases for the EpiPen allergy treatment.
Mylan CEO says company has no plans to lower price of EpiPens
Mylan CEO Heather Bresch takes her seat on Capitol Hill in Washington, Wednesday prior to testifying before the House Oversight Committee hearing on EpiPen price increases. Bresch defended the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
Crop science execs defend mergers; NC Senator cites regulation as driving deals
Top officials for Monsanto and Bayer defended their proposed $66 billion merger before skeptical senators on Tuesday, insisting that the deal would lead to greater investments in technology that could help American farmers. Monsanto, the American seed and weed-killer, and Bayer, the German medicine and farm-chemical maker, responded to concerns from Iowa Sen. Charles Grassley, the Republican chairman of the Senate Judiciary Committee.